T-DXd耐药机制:HER2表达缺失与结合界面突变
该研究通过对T-DXd治疗前后配对标本的分子分析,发现49%的病例在进展时HER2表达大幅下降,其中52%完全缺失HER2。同源模型证实HER2表达下降导致T-DXd内化减少和IC50值显著升高;并鉴定出位于曲妥珠单抗结合界面的ERBB2突变(V597M和P593R)可促进T-DXd耐药。低剂量T-DXd联合TROP2靶向ADC可更均匀地递送DXd载荷,克服HER2缺失介导的耐药。
要点
- T-DXd耐药机制包括HER2表达下降或完全缺失以及ERBB2结合界面突变。
- HER2表达下降减少T-DXd内化并大幅提高药物IC50值。
- 低剂量T-DXd联合TROP2 ADC可克服HER2缺失介导的耐药。
核心结论
- T-DXd耐药可由HER2表达缺失和曲妥珠单抗结合界面ERBB2突变导致靶点结合丧失所介导。
- 低剂量T-DXd联合TROP2靶向ADC可更均匀递送DXd载荷,克服HER2缺失介导的耐药。
研究设计与样本
- 研究对T-DXd治疗前后配对患者标本进行分子特征分析。
- 利用同源模型系统验证HER2表达下降与T-DXd内化及IC50值的关系。
- 鉴定并验证ERBB2突变(V597M和P593R)对T-DXd耐药的作用。
主要发现
- 49%的病例在进展时HER2表达大幅下降。
- HER2表达下降的病例中52%表现为HER2完全缺失。
- HER2表达下降对应T-DXd内化减少和肿瘤生长抑制的IC50值大幅增加。
- 位于曲妥珠单抗结合界面的ERBB2突变(V597M和P593R)可促进T-DXd耐药。
临床怎么用
- 对T-DXd进展患者可评估HER2表达缺失及ERBB2结合界面突变以明确耐药机制。
- 低剂量T-DXd联合TROP2靶向ADC可能是克服HER2缺失介导耐药的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Trastuzumab Deruxtecan (T-DXd) is clinically beneficial in HER2-positive and HER2-low metastatic breast cancer. However, therapeutic resistance emerges over time in most patients, with poorly defined resistance mechanisms. Through a molecular characterization of paired patient specimens before and after T-DXd treatment, we found that 49% cases had major decreases in HER2 expression at progression, and among them, 52% exhibited complete HER2 loss. Using isogenic model systems, we demonstrated that decreases in HER2 expression corresponded to reductions in T-DXd internalization and major increases in drug IC50 value for tumor growth inhibition. We further identified and validated ERBB2 mutations in the trastuzumab binding interface (V597M and P593R) that promoted T-DXd resistance. As a strategy to overcome impaired T-DXd binding and internalization, we tested low-dose combinations of T-DXd with TROP2-directed antibody-drug conjugates (ADC) and found that these could more uniformly deliver DXd payloads and thereby overcome resistance mediated by HER2 loss. SIGNIFICANCE: The mechanisms underlying clinical T-DXd resistance have not been established. We now report on two mechanisms of resistance that converge on loss of target binding and propose combinations of distinct ADCs with shared payloads as a strategy to overcome resistance by enhancing intratumor delivery. See related commentary by O'Meara and Tarantino, p.195.
引用
- Chen W, Gupta A, Mai N, et al. Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding. Cancer Discov. 2026. PMID: 41212147. doi:10.1158/2159-8290.CD-25-0647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。